BAX 888Alternative Names: FVIII gene therapy
Latest Information Update: 12 Nov 2016
At a glance
- Originator Baxalta
- Developer Shire
- Class Gene therapies
- Mechanism of Action Blood coagulation factor replacements; Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 03 Jun 2016 Baxalta has been acquired and merged into Shire